b-Arrestins in the Central Nervous System - Progress in Molecular Biology and Translational Science - page 280

36. Sotnikova TD, Budygin EA, Jones SR, Dykstra LA, Caron MG, Gainetdinov RR.
Dopamine transporter-dependent and -independent actions of trace amine beta-phen-
ylethylamine. J Neurochem . 2004;91(2):362- 373.
37. Seeman P, Weinshenker D, Quirion R, et al. Dopamine supersensitivity correlates
with D2High states, implying many paths to psychosis. Proc Natl Acad Sci USA .
2005;102(9):3513- 3518.
38. Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, Caron MG. Differential
regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases
and beta-arrestins. J Biol Chem . 2001;276(40):37409- 37414.
39. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Molecular determinants
underlying the formation of stable intracellular G protein-coupled receptor-

beta-arrestin complexes after receptor endocytosis. J Biol Chem . 2001;276

(22):19452 - 19460.
40. Lan H, Teeter MM, Gurevich VV, Neve KA. An intracellular loop 2 amino acid res-
idue determines differential binding of arrestin to the dopamine D2 and D3 receptors.
Mol Pharmacol . 2009;75(1):19- 26.
41. Bychkov E, Zurkovsky L, Garret MB, Ahmed MR, Gurevich EV. Distinct cellular and
subcellular distributions of G protein-coupled receptor kinase and arrestin isoforms in
the striatum. PLoS One . 2012;7(11):e48912.
42. Macey TA, Gurevich VV, Neve KA. Preferential interaction between the dopamine
D2 receptor and arrestin2 in neostriatal neurons. Mol Pharmacol . 2004;66(6):1635 - 1642.
43. Skinbjerg M, Ariano MA, Thorsell A, et al. Arrestin3 mediates D(2) dopamine receptor
internalization. Synapse . 2009;63(7):621- 624.
44. Bohn LM, Gainetdinov RR, Sotnikova TD, et al. Enhanced rewarding properties of
morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci . 2003;23
(32):10265 - 10273.
45. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG.
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotrans-
mission and behavior. Cell . 2005;122(2):261- 273.
46. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of gly-
cogen synthase kinase-3 by insulin mediated by protein kinase B. Nature . 1995;378
(6559):785 - 789.
47. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein
kinase B by insulin and IGF-1. EMBO J . 1996;15(23):6541- 6551.
48. Scheid MP, Woodgett JR. PKB/AKT: functional insights from genetic models. Nat
Rev Mol Cell Biol . 2001;2(10):760 - 768.
49. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex
integrity and regulates Akt phosphorylation and substrate specificity. Cell . 2006;127
(1):125 - 137.
50. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. Glycogen synthase
kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation.
J Biol Chem . 2002;277(12):9684 - 9689.
51. Woodgett JR. Physiological roles of glycogen synthase kinase-3: potential as a thera-
peutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol
Disord . 2003;3(4):281- 290.
52. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-
dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cas-
cade. Proc Natl Acad Sci USA . 2004;101(14):5099 - 5104.
53. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Role of GSK3beta in behavioral abnor-
malities induced by serotonin deficiency. Proc Natl Acad Sci USA . 2008;105
(4):1333- 1338.